Adaia Albasanz‐Puig

Author

Adaia Albasanz‐Puig

Also Known As

A Albasanz‐Puig, A. Albasanz-Puig, A. Albasanz‐Puig, Adaia Albasanz, Adaia Albasanz Puig, Adaia Albasanz-Puig, Adaia Albasanz‐Puig, Álvarez-Uría A.

Publications

693

Citations

H-Index

Concepts

All Affiliations

Instituto de Salud Carlos III Universitat de Barcelona Institut Català d'Oncologia Institut d'Investigació Biomédica de Bellvitge Bellvitge University Hospital

About

Adaia Albasanz‐Puig is an author at Instituto de Salud Carlos III specializing in medicine, atherosclerosis, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	172
2	Cell Biology	2	2	58
3	Health Sciences	1	1	29
4	Cellular Physiology	1	1	29
5	Cellular Therapies	1	1	38

Adaia Albasanz‐Puig

Publications

506

Citations

H-Index

Page 1

	Year	Citations
Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance Gemma Martínez‐Nadal, Pedro Puerta‐Alcalde, Carlota Gudiol, Clinical Infectious Diseases	2019	154
Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa Carlota Gudiol, Adaia Albasanz‐Puig, Júlia Laporte-Amargós, Antimicrobial Agents and Chemotherapy	2020	58
Oncostatin M is expressed in atherosclerotic lesions: A role for Oncostatin M in the pathogenesis of atherosclerosis Adaia Albasanz‐Puig, Jacqueline Murray, Michael R. Preusch, Atherosclerosis InflammationAtherosclerotic LesionsVascular DiseaseOncostatin MImmunology	2011	48
Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study) Adaia Albasanz‐Puig, Carlota Gudiol, Pedro Puerta‐Alcalde, Antimicrobial Agents and Chemotherapy	2021	48
Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy Ester Márquez‐Algaba, Gloria Iacoboni, Berta Pernas, Transplantation and Cellular Therapy Cell TherapyCytomegalovirus ReplicationImmunodeficienciesCmv ReplicationImmunology	2022	38
Opposing roles of STAT-1 and STAT-3 in regulating vascular endothelial growth factor expression in vascular smooth muscle cells Adaia Albasanz‐Puig, Jacqueline Murray, Mayumi Namekata, Biochemical and Biophysical Research Communications InflammationSignal TransductionAngiogenesisCell SignalingVascular Adaptation	2012	29
Modulation of vascular smooth muscle cell phenotype by STAT-1 and STAT-3 Mayumi Namekata Kirchmer, Anaïs Franco‐Romero, Adaia Albasanz‐Puig, Atherosclerosis InflammationVascular DiseaseAngiogenesisMolecular PhysiologyAtherosclerosis	2014	29
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study) Alba Bergas, Adaia Albasanz‐Puig, Ana Fernández‐Cruz, Microbiology Spectrum	2022	29
A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients Carlota Gudiol, Montserrat Arnán, Manuela Aguilar‐Guisado, Antimicrobial Agents and Chemotherapy	2019	20
Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis Agustín Pappolla, Luciana Midaglia, Claudia P. Boix Rodríguez, Neurology ImmunodeficienciesImmunologyImmunotherapyHumanized Monoclonal AntibodyViral Persistence	2018	15

Page 1